Is Amgen worth $61B to Pfizer?

Yesterday, Deutsche Bank analyst Barbara Ryan proposed a Pfizer-Amgen combo, becoming the third industry watcher to float that particular trial balloon. Today, BNet's Jim Edwards asks, "why not?" If you're an aficionado of the worst-case scenario--and a fan of deal speculation--these are the things you should know.

Does Pfizer look ready to do a deal? Well, the company announced it will be not increasing its dividend, fueling talk that it's hoarding cash to be ready to make the right offer. Is Amgen ready for a buyout? It looked ripe in March, when its stock traded around $40 and Credit Suisse's Catherine Arnold tagged it as a possible Pfizer target. Now, however, the stock has made gains, trading at above $55. So its price tag is lots bigger these days.

Not to mention the fact that, as Edwards points out, Pfizer would inherit a few Amgen problems ... er, challenges. Its anemia drug sales have dropped on safety concerns. Arthritis-and-psoriasis therapy Enbrel just got a new warning on its label, and it will face a competitor next year. Pfizer would be more interested in its late-stage pipeline, which contains five candidates, but carries uncertainty with it, as all drug candidates do. And Amgen has a profit-sharing deal with Wyeth that accounts for a big chunk of its sales-and-marketing-and-administrative expenses.

So is Amgen worth the some $61 billion it would cost now? To Pfizer, which keeps denying that it wants to make a mega-merger deal? You be the judge.

- read the post at BNet

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.